New Guidelines for Bronchodilator Responsiveness in COPD: A Test in Search of a Use.
作者信息
Bhatt Surya P, Fortis Spyridon, Bodduluri Sandeep
机构信息
University of Alabama at Birmingham Birmingham, Alabama.
University of Iowa Iowa City, Iowa.
出版信息
Am J Respir Crit Care Med. 2022 Oct 15;206(8):1042-1044. doi: 10.1164/rccm.202203-0458LE.
Abstract
摘要
相似文献
1
New Guidelines for Bronchodilator Responsiveness in COPD: A Test in Search of a Use.慢性阻塞性肺疾病支气管扩张剂反应性的新指南：一项寻求用途的测试
Am J Respir Crit Care Med. 2022 Oct 15;206(8):1042-1044. doi: 10.1164/rccm.202203-0458LE.
2
The role of bronchodilators in controlling COPD symptoms.支气管扩张剂在控制慢性阻塞性肺疾病（COPD）症状方面的作用。
Community Nurse. 2000 Jun;6(5):19-20.
3
Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry.揭示吸入性支气管扩张剂在慢性阻塞性肺疾病中的有益作用：超越用力肺活量测定法。
J Bras Pneumol. 2019 Jun 27;45(3):e20190168. doi: 10.1590/1806-3713/e20190168.
4
Early COPD patients with lung hyperinflation associated with poorer lung function but better bronchodilator responsiveness.伴有肺过度充气的早期慢性阻塞性肺疾病患者肺功能较差，但支气管扩张剂反应性较好。
Int J Chron Obstruct Pulmon Dis. 2016 Oct 7;11:2519-2526. doi: 10.2147/COPD.S110021. eCollection 2016.
5
Role of the Bronchodilator Test Defined by the Forced Vital Capacity in Chronic Obstructive Pulmonary Disease Phenotyping.用力肺活量定义的支气管扩张剂试验在慢性阻塞性肺疾病表型中的作用。
Int J Chron Obstruct Pulmon Dis. 2020 May 28;15:1199-1206. doi: 10.2147/COPD.S252902. eCollection 2020.
6
[Pathophysiological basis for using bronchodilatators in COPD].[慢性阻塞性肺疾病中使用支气管扩张剂的病理生理基础]
Rev Pneumol Clin. 2002 Sep;58(4 Pt 2):2S5-9.
7
[Bronchodilation in COPD. How can we increase efficiency?].[慢性阻塞性肺疾病中的支气管扩张。我们如何提高效率？]
Arch Bronconeumol. 2004 Mar;40 Suppl 1:30-3. doi: 10.1157/13077786.
8
Responsiveness to bronchodilator procaterol in COPD as assessed by forced oscillation technique.通过强迫振荡技术评估慢性阻塞性肺疾病（COPD）患者对支气管扩张剂丙卡特罗的反应性。
Respir Physiol Neurobiol. 2017 Jun;240:41-47. doi: 10.1016/j.resp.2017.02.012. Epub 2017 Feb 24.
9
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease.支气管扩张剂反应性作为已确诊慢性阻塞性肺疾病的一种表型特征。
Thorax. 2012 Aug;67(8):701-8. doi: 10.1136/thoraxjnl-2011-201458. Epub 2012 Jun 13.
10
Bronchodilator responsiveness: interpret with caution.支气管扩张剂反应性：谨慎解读。
Thorax. 2012 Aug;67(8):667-8. doi: 10.1136/thoraxjnl-2012-201966. Epub 2012 Jun 12.
引用本文的文献
1
ERS/ATS Global Lung Function Initiative normal values and classifying severity based on z-scores instead of per cent predicted.欧洲呼吸学会/美国胸科学会全球肺功能倡议的正常数值以及基于z评分而非预计百分比来划分严重程度。
Breathe (Sheff). 2024 Dec 10;20(3):230227. doi: 10.1183/20734735.0227-2023. eCollection 2024 Oct.
2
Assessing the Impact of the Updated 2021 European Respiratory Society/American Thoracic Society Criteria on Bronchodilator Responsiveness in Asthma.评估2021年更新的欧洲呼吸学会/美国胸科学会标准对哮喘患者支气管扩张剂反应性的影响。
Cureus. 2024 Aug 14;16(8):e66844. doi: 10.7759/cureus.66844. eCollection 2024 Aug.
3
Exploring the associations between elevated plasma SP-D levels and OSCAR gene expression as potential biomarkers in patients with COPD: a cross-sectional study.探索血浆表面活性蛋白-D（SP-D）水平升高与OSCAR基因表达之间的关联，作为慢性阻塞性肺疾病（COPD）患者的潜在生物标志物：一项横断面研究。
Front Pharmacol. 2024 Jul 18;15:1376394. doi: 10.3389/fphar.2024.1376394. eCollection 2024.
4
Prevalence of Bronchodilator Responsiveness: A Comparison of Old Versus New Criteria.支气管扩张剂反应性的流行率：新旧标准的比较。
Respir Care. 2024 Sep 26;69(10):1266-1274. doi: 10.4187/respcare.11603.
5
Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness.支气管舒张剂反应性的流行率、诊断效用及相关特征。
Am J Respir Crit Care Med. 2024 Feb 15;209(4):390-401. doi: 10.1164/rccm.202308-1436OC.
6
Prevalence, risk factors, and mortality of COPD in young people in the USA: results from a population-based retrospective cohort.美国年轻人中 COPD 的患病率、风险因素和死亡率：基于人群的回顾性队列研究结果。
BMJ Open Respir Res. 2023 Jul;10(1). doi: 10.1136/bmjresp-2022-001550.
7
Differences in clinical significance of bronchodilator responses measured by forced expiratory volume in 1 second and forced vital capacity.一秒用力呼气容积和用力肺活量测定的支气管扩张剂反应的临床意义差异。
PLoS One. 2023 Feb 24;18(2):e0282256. doi: 10.1371/journal.pone.0282256. eCollection 2023.
8
Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.吸烟人群中无论是否患有 COPD，支气管扩张剂的反应性。
Chest. 2023 Mar;163(3):502-514. doi: 10.1016/j.chest.2022.11.009. Epub 2022 Nov 15.
9
Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease.支气管扩张剂反应性的定义：2005 年和 2021 年 ERS/ATS 标准在哮喘以及慢性阻塞性肺疾病患者中的应用。
Int J Chron Obstruct Pulmon Dis. 2022 Oct 17;17:2623-2633. doi: 10.2147/COPD.S385733. eCollection 2022.
本文引用的文献
1
ERS/ATS technical standard on interpretive strategies for routine lung function tests.ERS/ATS 技术标准：常规肺功能测试的解释策略。
Eur Respir J. 2022 Jul 13;60(1). doi: 10.1183/13993003.01499-2021. Print 2022 Jul.
2
Combined Forced Expiratory Volume in 1 Second and Forced Vital Capacity Bronchodilator Response, Exacerbations, and Mortality in Chronic Obstructive Pulmonary Disease.一秒用力呼气容积与用力肺活量的支气管扩张剂反应、慢性阻塞性肺疾病加重和死亡率的关系。
Ann Am Thorac Soc. 2019 Jul;16(7):826-835. doi: 10.1513/AnnalsATS.201809-601OC.
3
Improved criterion for assessing lung function reversibility.评估肺功能可逆性的改良标准。
Chest. 2015 Oct;148(4):877-886. doi: 10.1378/chest.14-2413.
4
Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations.慢性阻塞性肺疾病的支气管扩张剂可逆性：应用及局限性。
Lancet Respir Med. 2013 Sep;1(7):564-73. doi: 10.1016/S2213-2600(13)70086-9. Epub 2013 Jun 18.
5
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations.用于 3-95 岁年龄范围的肺量测定的多民族参考值：全球肺功能 2012 方程。
Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27.
6
Genetic epidemiology of COPD (COPDGene) study design.COPD（COPDGene）遗传流行病学研究设计。
COPD. 2010 Feb;7(1):32-43. doi: 10.3109/15412550903499522.
7
Interpretative strategies for lung function tests.肺功能测试的解读策略。
Eur Respir J. 2005 Nov;26(5):948-68. doi: 10.1183/09031936.05.00035205.
8
Standardisation of spirometry.肺活量测定法的标准化
Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805.
9
Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease.可逆性和不可逆性气流阻塞作为哮喘和慢性阻塞性肺疾病总体死亡率的预测指标
Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1267-71. doi: 10.1164/ajrccm.159.4.9807121.
Zotero 插件